Effect of Kohl-Chikni Dawa – a compound ophthalmic formulation of Unani medicine on naphthalene-induced cataracts in rats

Background Cataracts are the leading cause of blindness worldwide, accounting for 13-27% of cases. Kohl-Chikni Dawa (KCD) is reputed for its beneficial effects in the treatment of premature cataracts. However, its efficacy is yet to be tested. To investigate the rationality of the therapeutic use of Kohl-Chikni Dawa (KCD) in Unani medicine.